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CancerAnticancer systemic gene silencing therapy has been so far limited by the inexistence of adequate carrier
systems that ultimately provide an efﬁcient intracellular delivery into target tumor cells. In this respect, one
promising strategy involves the covalent attachment of internalizing-targeting ligands at the extremity of
PEG chains grafted onto liposomes. Therefore, the present work aims at designing targeted liposomes
containing nucleic acids, with small size, high encapsulation efﬁciency and able to be actively internalized by
SCLC cells, using a hexapeptide (antagonist G) as a targeting ligand. For this purpose, the effect of the
liposomal preparation method, loading material (ODN versus siRNA) and peptide-coupling procedure (direct
coupling versus post-insertion) on each of the above-mentioned parameters was assessed. Post-insertion of
DSPE-PEG-antagonist G conjugates into preformed liposomes herein named as stabilized lipid particles,
resulted in targeted vesicles with a mean size of about 130 nm, encapsulation efﬁciency close to 100%, and a
loading capacity of approximately 5 nmol siRNA/μmol of total lipid. In addition, the developed targeted
vesicles showed increased internalization in SCLC cells, as well as in other tumor cells and HMEC-1
microvascular endothelial cells. The improved cellular association, however, did not correlate with enhanced
downregulation of the target protein (Bcl-2) in SCLC cells. These results indicate that additional
improvements need to be performed in the future, namely by ameliorating the access of the nucleic acids
to the cytoplasm of the tumor cells following receptor-mediated endocytosis.
© 2009 Elsevier B.V. All rights reserved.mall cell lung cancer; siRNA,
L, coated cationic liposomes;
ed nucleic acid lipid particles;
e; NaN3, sodium azide; AD,
ovine serum albumin; C12E8,
ated soy phosphatidylcholine;
16-PEG, N-palmitoyl-sphingo-
E-PEG, N-palmitoyl-sphingo-
al, 1,2-distearoyl-sn-glycero-
glycol)]2000; rhodamine-PE,
ne B sulfonyl); DOTAP, 1,2-
ioleyl-3-dimethylammonium-
; Tris, 2-amino-2-(hydroxy-
-1-piperazine-ethanesulfonic
S, HEPES buffered saline; SLP,
N; SLPsiRNA, SLP encapsulating
ter for Neuroscience and Cell
a, 3004-517 Coimbra, Portugal.
eutical Technology, Faculty of
ll rights reserved.1. Introduction
Systemic administration of anticancer gene silencing therapy has
been so far limited by the inexistence of adequate carrier systems.
Ideally, they should efﬁciently encapsulate the nucleic acids, be stable
in blood and present prolonged circulation times, without causing any
immune reactions. Moreover, carrier systems must be internalized by
cancer cells, where they should destabilize in the endosomal
compartment for an efﬁcient release of the active nucleic acids. The
best equilibrium between these properties is a true challenge, so far
difﬁcult to meet.
Different poly(ethylene glycol) (PEG)-grafted cationic liposomes
encapsulating antisense ODN such as coated cationic liposomes (CCL)
[1], stabilized antisense lipid particles (SALP) [2], or the related
stabilized nucleic acid lipid particles (SNALP) encapsulating siRNA
[3–6], have been developed in order to fulﬁll some of the above-
mentioned key requirements. However, in the treatment of cancer
there is still the need of more efﬁcient intracellular delivery of nucleic
acids, aiming at reaching an adequate pharmacodynamic perfor-
mance. In this context, one of the most promising strategies involves
the covalent attachment of a targeting ligand, at the extremity of PEG
chains grafted onto liposomes, which will speciﬁcally promote
intracellular accumulation of the nucleic acid-containing lipid particle
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silencing [7]. Such strategy is also particularly important when
dealing with tumor cells that are difﬁcult to transfect, as for example
SCLC [8,9], as internalization of the nucleic acids can be itself a limiting
step in this process.
The potential of ligand-mediated targeting of liposomes for the
treatment of SCLC has been assessed for the ﬁrst time by Moreira et al
[10]. The targeting ligand was a hexapeptide known as antagonist G
([Arg6,D-Trp7,9,MePhe8]substance P[6–11]), ﬁrst described as a
broad-spectrum antagonist, active against several receptors of the
G-protein coupled receptor family [11], and more recently described
to be a biased agonist of gastrin-releasing peptide and vasopressin V1A
receptors [12]. It was used as a targeting agent for sterically stabilized
liposomes containing doxorubicin in human SCLC, either upon
coupling to preformed liposomes (direct coupling) [10], or by post-
insertion of the conjugate DSPE-PEG-antagonist G from a micellar
phase into preformed liposomes [13]. One of the challenges posed by
the preparation of ligand-targeted liposomes containing nucleic acids,
with the direct coupling procedure, comes from the susceptibility to
hydrolysis of maleimide groups, currently used in PEG-derivatized
lipids for bioconjugation. It might lead to the formation of non-
reactive groups, thus compromising the efﬁciency of the coupling
procedure [14]. Moreover, a ligand like antagonist G, short and highly
hydrophobic, that easily insert into membranes [15,16], might lead to
aggregation of the liposomes during the coupling reaction, thus
compromising their systemic administration. Therefore, the post-
insertion of ligand-derivatized conjugates onto preformed liposomes
is expected to provide a simpler and more ﬂexible method to prepare
antagonist G-targeted liposomes containing nucleic acids. However,
when this approach was tested before with liposomes containing
doxorubicin, it was observed that the transfer of antagonist G
conjugates caused the release of a high percentage of drug. This was
circumvented by remote loading of doxorubicin after the post-
insertion had taken place [13]. In the case of similar problems with
the encapsulation of nucleic acids, the previous solution would not be
applicable.
The present work aims at designing an antagonist G-targeted non-
viral lipid-based particle containing nucleic acids, with small size, high
encapsulation efﬁciency and able to be actively internalized by SCLC
cells (as compared to non-targeted particles). For this purpose, the
effect of the preparation method (CCL versus SALP), loading material
(ODN versus siRNA) and coupling method (direct method versus
post-insertion) in each of the previously mentioned issues was
assessed. These are important parameters that need to be character-
ized before the in vivo application of antagonist G-targeted liposomes.
2. Materials and methods
2.1. Materials
All salts were either SIGMA® (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany) or Merck (Darmstadt, Germany). Actinomycin
D (AD), 7-aminoactinomycin D (7-AAD), bovine serum albumin
(BSA), RPMI 1640 with L-glutamine and without sodium bicarbonate,
penicillin–streptomycin solution (10,000 U/ml and 10 mg/ml,
respectively), 2-iminothiolane hydrochloride, digitonin, sodium salt
of 2-(n-morpholino)ethanesulfonic acid (MES), mouse epidermal
growth factor (EGF), hydrocortisone, cholesterol (CHOL), gel ﬁltration
media Sephadex® G-50 and DEAE Sepharose® CL-4B, 2-iminothiolane
hydrochloride, LY-294,002, Hoechst 33342, and silicon coating
reagent (Sigmacote) were SIGMA® (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany). Fetal bovine serum (FBS) was Gibco® (Invitro-
gen S.A., Barcelona, Spain). Octaethylene glycol monododecyl ether
(C12E8) was Fluka® (Sigma-Aldrich Chemie GmbH, Steinheim,
Germany). Fully hydrogenated soy phosphatidylcholine (HSPC), 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), N-palmitoyl-sphin-gosine-1-succinyl(methoxypolyethylene glycol)2000 (CerC16-PEG),
ammonium salts of N-palmitoyl-sphingosine-1-[succinyl(polyeth-
ylene glycol)]2000 (DSPE-PEG), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)]2000
(DSPE-PEG-Mal), and L-α-phosphatidylethanolamine-N-(lissamine
rhodamine B sulfonyl) (rhodamine-PE), and chloride salts of 1,2-
dioleyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleyl-3-
dimethylammonium-propane (DODAP), were purchased from Avanti
Polar Lipids, Inc. (Alabaster, AL).
The hexapeptide antagonist G (NH2-Arg-[D-Trp]-NmePhe-[D-Trp]-
Leu-Met-CONH2) was synthesized by Prim srl, (Milan, Italy) with a
purity N95%. ODN 2009 (desalted 20-mer phosphorothioate [17]) was
purchased from University Core DNA services, (University of Calgary,
Calgary, AB, Canada). The carboxyﬂuorescein-conjugated ODN 2009
was purchased from Microsynth (Balgach, Switzerland). The anti-
BCL2 siRNA and the control non-targeting siRNA (siRNA nt) were
purchased from Dharmacon Inc. (Lafayette, CO) in the form of
deprotected, annealed and desalted duplexes. Upon solubilization in
ultra pure water or Dharmacon's siRNA buffer (20 mM KCl, 0.2 mM
MgCl2, 6 mM HEPES, pH 7.5), the concentration of the stock solutions
of both ODN and siRNAwas conﬁrmed by absorbance at 260 nm using
the corresponding extinction coefﬁcient.
2.2. Cell lines
The human variant SCLC cell line SW2 was kindly provided by Drs.
U. Zangemeister-Wittke and R. Stahel (University Hospital of Zurich,
Switzerland). The human classic NCI-H69 SCLC cells, and the human
non-small cell lung cancer (NSCLC) A549 cells were from the
American Type Culture Collection (Manassas, IL). The human
microvascular endothelial cell line HMEC-1 was a generous gift from
the Centers for Disease Control and Prevention (Atlanta, GA). Cells
were cultured in RPMI 1640 supplemented with 10% (v/v) heat-
inactivated FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 10 mM
HEPES and 0.2 % NaHCO3, at 37 °C, in a humidiﬁed atmosphere (90%),
containing 5% CO2. HMEC-1 culture medium was also supplemented
with 10 ng/ml mEGF and 1 μg/ml hydrocortisone. Cells were
maintained in exponential growth phase and periodically tested for
mycoplasma contamination with MycoAlert® Mycoplasma Detection
kit (Cambrex Bio Science Verviers, Inc., Liege, Belgium).
2.3. Preparation of coated cationic liposomes
The procedure of CCL preparation by reverse phase evaporation
was adapted from Stuart et al. [1]. The ODN 2009 at 2 mg/ml in 250 or
500 μl of water was incubated with the cationic lipid DOTAP in an
equivalent volume of chloroform, at an ODN/DOTAP (−/+) charge
ratio of 1, upon addition of methanol (in a small excess of 0.5 or 1 ml)
to form a Bligh-Dyer monophase where hydrophobic ODN-lipid
particles are formed. After 30 min of incubation, separation of phases
was achieved through addition of another 250 or 500 μl of water and
chloroform, followed by centrifugation (7 min at 800×g). The organic
phase containing the formed hydrophobic ODN-DOTAP particles was
then mixed with the neutral lipids solubilized in chloroform (HSPC:
CHOL:[DSPE-PEG or DSPE-PEG-Mal] at the molar proportion of
3:2:0.2, relative to DOTAP, with or without 1 mol% rhodamine-PE,
achieving a total lipid concentration of around 32 mM. When CCL
were submitted to post-insertion of PEG-conjugates, the amount of
DSPE-PEG originally incorporated was reduced to half. The resulting
organic solution was transformed into a stable w/o emulsion by
addition of water (1/3 of the chloroform volume) and sonication for
30 min. The emulsion was reversed upon chloroform evaporation
under reduced pressure until a gel phase was formed, time at which
the addition of more water (the necessary volume to reach 10 mM of
lipid) and further evaporation, completed gel reversion, resulting in
the formation of liposomes. During this process, samples were
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raised with N2. The resulting liposomes were then extruded 11 times
sequentially through polycarbonate membranes of 400, 200 and
100 nm pore size using a LipoFast mini extruder pre-heated at ∼65 °C
(Liposofast, Avestin Europe GmbH, Mannheim, Germany) to obtain a
uniform size distribution [18]. The liposomes were then run down a
Sephadex G-50 column equilibrated either with MES-buffered saline
(MBS) (25 mM MES, 129 mM NaCl) pH 6.5, or with HEPES buffered
saline (HBS) (25 mMHEPES, 140 mMNaCl), pH 7.4, depending on the
coupling method the formulation was planned to be used for (section
2.6).
2.4. Preparation of stabilized antisense lipid particles
In this work, a second method of preparation of targeted lipid-
based nanoparticles was used. The procedure to prepare SALP was
adapted from Semple et al. [2]. The lipid mixture (either formulation
A, DODAP:DSPC:CHOL:DSPE-PEG-Mal, 25:20:45:10, or formulation B,
DODAP:DSPC:CHOL:CerC16-PEG, 25:20:45:8) prepared in 100% etha-
nol at approximately 50 mM total lipid was added to ODN diluted in a
20-mM citrate-buffered solution at pH 4, preheated at 60 °C, under
vortex agitation. The ﬁnal proportion of ethanol was ∼40%. The
resulting vesicles were then extruded 21 times through polycarbonate
membranes of 100 nm pore size at ∼65 °C using a LipoFast mini
extruder. Liposomes were either directly chromatographed with a
DEAE Sepharose® CL-4B column equilibrated with MES, pH 6.5 and
submitted to direct coupling of antagonist G (formulation A), or
dialyzed using a regenerated cellulose tubular membrane Cellu.Sep
T2, of nominal MW cut off of 6000–8000, for 3 h against 25mMHEPES
buffer, pH 7.4, and then submitted to post-insertion (formulation B),
as described in Section 2.6.
2.5. Modiﬁed procedure for the preparation of stabilized lipid particles
A modiﬁed formulation based in the previous described SALP,
named stabilized lipid particles (SLP), was used for the encapsulation
of either ODN (SLPODN) or siRNA (SLPsiRNA). The liposomes were
formed by DOTAP:DSPC:CHOL (16:24:45 mol%), and CerC16-PEG +
[DSPE-PEG or DSPE-PEG-Mal] (6+4 mol%) or CerC16-PEG only
(8 mol%), and with or without rhodamine-PE (usually 1 mol%). The
lipid mixture prepared in 2/5 of the ﬁnal volume in 100% ethanol, at
approximately 50 mM of total lipid, was added in a charge ratio of 1:1
to the ODN or siRNA diluted in 25 mM citrate buffer, pH 6, preheated
at 60 °C, under vortex agitation. The resulting vesicles, now in ∼40%
ethanol, were then extruded 21 times through polycarbonate
membranes of 100 nm pore size at ∼65 °C using a LipoFast mini
extruder. Liposomes were either dialyzed for 3 h against MBS pH 6.5,
or submitted to size exclusion chromatography in a DEAE Sepharose®
CL-4B column, equilibrated with MBS pH 6.5, and then submitted to
post-insertion or direct coupling procedures, as described in Section
2.6.
2.6. Covalent coupling of antagonist G to micelles of DSPE-PEG-Mal,
post-insertion, and direct coupling
Coupling of antagonist G to PEG-derivatized DSPE has been
adapted from previous reports [13]. Peptide thiolation [19] took
place upon reaction of 0.35 mM antagonist G with 2-iminothiolane at
1:4 molar ratio in 12.5 mM HEPES, 1 mM EDTA, pH 8, for 1 h at room
temperature, in an inert N2 atmosphere, and in a silicon-coated glass
vial. Thiolated antagonist G was then added to 0.35 mM DSPE-PEG-
Mal micelles, suspended in MBS, pH 6.5, at a lipid/peptide molar ratio
of 1:1. Coupling reaction took place overnight at room temperature in
an inert N2 atmosphere. For post-insertion, micelles of targeted
conjugate (or control DSPE-PEG micelles) were incubated with the
liposomes for 1 h at 60 °C, at a conjugate/total lipid ratio of 2 mol%.Alternatively, in the so-called direct coupling procedure, the
thiolated peptide was added to DSPE-PEG-Mal-grafted liposomes in
MBS and the reaction took place as described in the previous
paragraph. When required, excess maleimide was quenched by
reaction with an excess of 2-mercaptoethanol for 30 min. The
resulting liposomes were puriﬁed by size exclusion chromatography
in Sepharose CL-4B columns equilibrated with HBS, pH 7.4, in both
coupling procedures. Separation of free siRNA was always performed
with Sepharose CL-4B.
2.7. Physicochemical characterization of the liposomal formulations
The size dispersion of liposomes was evaluated by photon
correlation spectroscopy with a N5 submicron particle size analyzer
(Beckman Coulter, Inc. Fullerton, CA), upon dilution in ﬁltered HBS.
The encapsulation efﬁciency (EE) is the percentage of the ratio
between the nucleic acid to lipid molar ratio in the ﬁnal liposome
dispersion and that one in the initial mixture (liposome dispersion
before extrusion). ODN and RNA were quantiﬁed by using the Quant-
iT™ RiboGreen® RNA reagent (Invitrogen S.A. Barcelona, Spain) in the
presence of C12E8 detergent. The total lipid concentration was
inferred from cholesterol concentration determined with Inﬁnity™
cholesterol liquid stable reagent (ThermoTrace Ltd, Victoria,
Australia).
2.8. Quantitative evaluation of liposomes cellular association
Tumor cells (0.5×106) were incubated with rhodamine-labeled
liposomes in cell culture medium for 1 h and further washed three
times with ∼3 ml of PBS. Washed cells were transferred to 96-well
plates in 100 μl PBS, and lysed with 100 μl of lysis buffer (25 mM
HEPES, 2 mM EDTA, 1.2 mM C12E8, pH 8). Rhodamine-PE ﬂuores-
cence was measured in the supernatant in a SpectraMax Gemini EM
plate reader ﬂuorimeter (Molecular Devices, Sunnyvale, CA) at
545 nm/570 nm/587 nm excitation/cut-off/emission wavelengths.
The amount of cell-associated lipid was drawn from calibration curves
comparing lipid concentration and relative ﬂuorescence units. In
experiments with adherent cells, (plated the day before), the results
were normalized by determining the total protein of each well with
the BCA™ Protein Assay Kit (Pierce, ThermoFisher Scientiﬁc, Rockford,
IL, USA).
2.9. Qualitative evaluation of liposome association to SCLC cells by
ﬂow cytometry and confocal ﬂuorescence microscopy
SCLC SW2 cells (1×106), suspended in the culture medium
mentioned in Section 2.2, were incubated with SLPODN prepared by
post-insertion, labeled with rhodamine-PE (membrane marker) and
containing carboxyﬂuorescein-labeled ODN (25% of total ODN
content), at 0.6 mM of total lipid, for 1 h at 37 °C. At the end of the
incubation, half of the SW2 cells were washed and resuspended in
PBS, and a minimum of 10000 events were immediately acquired in a
ﬂow cytometer (BD FACSCalibur™, BD Biosciences, Erembodegem,
Belgium). The other half of SW2 cells was centrifuged and resus-
pended in fresh medium, and incubated at 37 °C for another 5 h.
Following this period, SW2 cells were ﬁxed with 4% paraformaldeyde
in PBS for 20 min at room temperature, washed with PBS, and stained
with Hoechst 33342 (1 μg/ml in PBS, for 5 min). After a ﬁnal washing
step, cells were gently spread over the glass andmounted onMowiol®
mounting medium (Calbiochem®, Bad Soden, Germany). Confocal
images were acquired in a Zeiss LSM-510 Meta laser-point scanning
confocal microscope (Zeiss, Jena, Germany), with a 63× Plan
Apochromat oil immersion objective, using a diode (405 nm), an
argon (488 nm) and a DPSS (561 nm) excitation lasers, and LSM-510
Meta software. Emission of Hoechst, carboxyﬂuorescein and rhoda-
mine were measured with BP 420–480, BP 505–550 and 572–700 nm
Fig. 1. Encapsulation efﬁciency of different antagonist G-targeted and non-targeted
formulations as a function of the preparation method and coupling procedure. The ODN
encapsulation efﬁciency was compared among antagonist G-targeted CCL, SALP and
SLPODN prepared by either the direct coupling or post-insertion methods (A). The
encapsulation efﬁciency of siRNA was compared between non-targeted (SLPsiRNA) and
antagonist G-targeted (SLPsiRNA-G) SLP, prepared by either the direct coupling or post-
insertion methods (B). Bars are the mean±SD of independent experiments. ‘⁎’ symbols
represent the signiﬁcance level of the difference between formulations (two-way
ANOVA, Bonferroni's post test).
436 A.O. Santos et al. / Biochimica et Biophysica Acta 1798 (2010) 433–441ﬁlters, respectively. All instrumental parameters pertaining to
ﬂuorescence detection and image analyses were held constant to
allow sample comparison.
2.10. Evaluation of the mechanism of internalization of antagonist
G-targeted liposomes
Aiming at evaluating the cell-entry pathway of antagonist-G
targeted liposomes, 1×106 SCLC H69 cells, suspended in the culture
medium mentioned in section 2.2, were preincubated for 30 min at
37 °C with non-toxic concentrations of drugs that inhibit different cell
entry pathways, including: hypertonic medium (0.45 M sucrose),
200 μM genistein or 50 μM LY-294,002; or at 4 °C for 1 h. Liposomes
were then added at 0.1 mM of total lipid, and further incubated for 1
h at 37 or 4 °C. The cellular association for each one of the tested
conditions was expressed in percentage and normalized for the
uptake of targeted liposomes at 37 °C for 1 h, without pretreatment
with drug inhibitors. In parallel, similar cellular association experi-
ments were performed with Alexa Fluor® 546 transferrin conjugate
(AlexaF-transferrin), (Molecular Probes, Invitrogen S.A., Barcelona,
Spain), at 100 μg/ml, aiming at assessing the extent of the drug
inhibitors effect in the clathrin-mediated endocytosis pathway.
2.11. Evaluation of Bcl-2 knockdown
SW2 cells (1–2×106 cells/ml), suspended in the culture medium
mentioned in Section 2.2, were incubated with 2 μM anti-BCL2-siRNA
or siRNA nt encapsulated in non-targeted or antagonist-G targeted
SLP for 6 h, and further centrifuged and resuspended in freshmedium.
Bcl-2 levels were evaluated at 72 h post transfection. At the end of the
experiment, approximately 0.2×106 tumor cells were incubated with
7-AAD (20 μg/ml) for 15 min at 4 °C in 0.1 ml of PBS, then washed
once and ﬁxed in 1% PFA for 20 min at 4 °C. Afterwards, cells were
washed with 1 ml of buffer containing 1% BSA, 0.1% NaN3 and 20 μg/
ml AD, and incubated for 15 min in 0.2 ml of the previous solution
containing 0.5 mg/ml digitonin and 8 μl of phycoerythrin-conjugated
mouse anti-human Bcl-2 mAb (IgG1k, clone Bcl-2/100, BD Pharmin-
gen™, BD Biosciences, Erembodegem, Belgium) or the same volume of
the correspondent phycoerythrin-conjugated isotype control (IgG1k,
clone MOPC-21, BD Pharmingen™, BD Biosciences). After washing
once with PBS containing BSA and NaN3, about 30,000 events cells
were acquired in a ﬂow cytometer (BD FACSCalibur™, BD Biosciences,
Erembodegem, Belgium) and analyzed as described elsewhere [20].
2.12. Statistical analysis
Plots display data as mean±SEM or SD, as mentioned in the
legends of the ﬁgures. Differences were evaluated by one-way or two-
way analysis of variance (ANOVA), with post-test analysis, depending
on the study design, and signiﬁcance levels indicated with symbols
(⁎pb0.05; ⁎⁎pb0.01; and ⁎⁎⁎pb0.001).
3. Results and discussion
Different liposomal formulations have been used to deliver nucleic
acids to cancer cells. One of themost widely used systems involves the
mixture of preformed cationic liposomes with nucleic acids (origi-
nating lipoplexes). The excess of positive charge provides an efﬁcient
encapsulation of the negatively charged molecules as well as an
efﬁcient delivery of the associated nucleic acid, following electrostatic
interaction with the negatively charged target cell membrane [21].
Although lipoplexes are efﬁcient transfection agents for in vitro
applications, they are usually not adequate for systemic administra-
tion. Lipoplexes present toxicity and inadequate biodistribution due
to their instability, propensity to form large aggregates, and extensive
clearance by the mononuclear phagocyte system (reviewed in [22]).In situ administrations using lipoplexes have been studied [23–25],
but are not adequate to address a systemic disease such as SCLC.
CCL [1] and SALP [2] are examples of formulations that encompass
a number of physicochemical features, such as efﬁcient encapsulation
of nucleic acids, good physical and biological stability as well as small
size (100–200 nm), which make them suitable for systemic
administration. For this reason, these formulations were selected to
develop antagonist G-targeted sterically stabilized liposomes contain-
ing nucleic acids.
3.1. Effect of the liposomal preparation method and coupling
procedure on the nucleic acid encapsulation efﬁciency
In a ﬁrst stage, the effect of two different coupling methods and of
the liposomal preparation procedure on the encapsulation efﬁciency
of both ODN and siRNA was assessed. One method involved the
covalent coupling of the thiolated antagonist G to the distal end of
Mal-PEG-derivatized lipid grafted onto CCL or SALP (herein designat-
ed as direct coupling method). In the procedure referred as post-
insertion, thiolated antagonist G was coupled to DSPE-PEG-Mal
micelles, and the resulting DSPE-PEG-peptide conjugates (DSPE-
PEG-G)were then transferred to preformed liposomes, as described in
Section 2.
The preparation of antagonist G-targeted CCL containing ODN,
either through direct coupling or post-insertion, led to encapsulation
efﬁciencies around 60% (Fig. 1A). When targeted liposomes were
prepared from SALP, also by both direct coupling and post-insertion
methods, encapsulation efﬁciency of ODN decreased to 40% and 20%,
respectively (Fig. 1A). The post-insertion to SALP took place at pH 7.4,
at a temperature above the melting temperature (∼60 °C), which
might have led to partial liposomal destabilization. Such destabiliza-
tion, at a pH where DODAP is neutral (intrinsic pKa of ∼6.6–7 [26]),
might have favored ODN leakage. In fact this was the reason why, in
order to make the insertion of DSPE-PEG-G conjugates possible,
DODAP was replaced by DOTAP (giving rise to the herein referred
Stabilized Lipid Particles, SLP), a lipid that is protonated during post-
insertion. It was thus possible to signiﬁcantly improve the encapsu-
lation efﬁciency of ODN, from about 20% to close to 60% (Fig. 1A). The
ODN encapsulation efﬁciency observed between the antagonist G-
targeted CCL, SALP and SLPODN and each of the corresponding non-
targeted formulationswas not signiﬁcantly different (data not shown).
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developed SLP formulation (SLPsiRNA), the resulting antagonist G-
targeted liposomes presented higher encapsulation efﬁciency when
prepared by the post-insertion as compared with the direct coupling
method (Fig. 1B). It is important to point out that using the direct
coupling procedure, the incubation of the thiolated antagonist G with
preformed liposomes led to a 2-fold decrease of the encapsulation
efﬁciency relative to non-targeted liposomes (Fig. 1B). A similar effect
was also observed when this coupling procedure was performed with
liposomes containing doxorubicin, although at a lower extent (10% of
drug leakage; JN Moreira, unpublished observations). These observa-
tions are therefore a strong indication that the free targeting peptide,
interfered with the ﬁnal encapsulation yield of siRNA. Overall,
regarding encapsulation efﬁciency, the use of CCL or SLP, followed
by post-insertion of antagonist G conjugate, were the best method-
ologies to prepare antagonist G-targeted liposomes. The overall
loading of nucleic acids (5–6 nmol ODN or 4–5 nmol siRNA/μmol
total lipid) was comparable with the values obtained by others [1,5].
3.2. Mean size of the different non-targeted and antagonist G-targeted
liposomes
The size of any non-viral particle aiming at systemic gene silencing
plays a major role in its pharmacodynamic performance, affecting
both the circulation time in the blood and the passive accumulation
into a tumor (EPR effect) [27].
In line with what has been shown in the previous section, direct
coupling of antagonist G to both CCL and SLP was also disadvanta-
geous in terms of the vesicles ﬁnal size, as compared to the non-
targeted counterparts. It led to a signiﬁcant increase of the mean size
(p=0.001, two-way ANOVA; Fig. 2A), polydispersity index (data not
shown) as well as average size dispersion, relative to non-targeted
formulations, particularly for CCL (185±24 nm and 326±135 nm, for
CCL and CCL-G, respectively). Both non-targeted and antagonist G-
targeted SLP prepared by direct coupling were signiﬁcantly smaller
than the corresponding CCL (p=0.004, two-way ANOVA). The mean
size of antagonist G-targeted SLPwas approximately 200 nm (Fig. 2A),
a value still suitable for systemic administration.
The preparation of antagonist G-targeted CCL upon incubation of
preformed liposomes with 2 mol% DSPE-PEG-G micelles led to
vesicles with a mean size that was not signiﬁcantly different from
that of non-targeted liposomes (190±34 nm and 155±3 nm,
respectively, Fig. 2B). Similarly, the post-insertion of antagonist G
conjugate into SLP did not change the size of the resulting vesicles
(131±8 nm and 126±3 nm, respectively, Fig. 2B) and the overallFig. 2.Mean size of different non-targeted and antagonist G-targeted formulations as a
function of the preparation method. Antagonist G-targeted liposomes were prepared
from CCL or SLP (encapsulating either ODN or siRNA) using the direct coupling (A) or
post-insertion method (B). The size dispersion of liposomes was evaluated by photon
correlation spectroscopy. Bars represent the mean±SD of 3 to 10 independent
experiments. ‘⁎’ symbols represent the signiﬁcance level of the difference between
formulations (two-way ANOVA, Bonferroni's post-test).mean size was even slightly lower than the one obtained with CCL
(p=0.002, two-way ANOVA; Fig. 2B). The reduced mean size
dispersion was an indication of the reproducibility of the liposomal
preparation process. The same observation can be extended to SALP
(data not shown), although the encapsulation efﬁciency was only
around 20%, as demonstrated in the previous section.
Overall, the results gathered regarding mean size and encapsula-
tion efﬁciency of antagonist G-targeted liposomes containing nucleic
acids, demonstrate that the post-insertion of DSPE-PEG-G into either
CCL or SLP results in physico-chemical features that better meet the
requirements of a targeted non-viral particle aiming at systemic gene
silencing for cancer treatment.
3.3. Cellular association of antagonist G-targeted CCL and SLP liposomes
All the formulations used in the present work are characterized by
the presence of an amount of PEG that ranges from 3.2 mol% (CCL) to
10 mol% (SALP and SLP) relative to total lipid. The advantages of using
PEG are undoubtedly recognized. It provides the nanoparticle with
long circulation times in blood and further accumulation in distant
sites of disease such as solid tumors [28]. In the case of formulations
like CCL and SLP/SALP, the presence of PEG also allows the ﬁnal size of
the nucleic acid-containing lipid-based nanoparticle to be controllable
within a range adequate for systemic administration [1,26]. The
downside of the presence of PEG is the signiﬁcant reduction in the
extent of the liposomal cellular association [29], as it was also
evidenced for non-targeted SALP (data not shown), CCL, and SLP
formulations (Fig. 3). In addition, SCLC cells are intrinsically difﬁcult to
transfect [8,9], and antagonist G can, therefore, provide an added
value to the nanoparticle. Antagonist G was ﬁrst described as a broad-
spectrum antagonist, active against several receptors of the family of
G-protein coupled receptor family [11], and more recently has been
shown to be a biased agonist of gastrin-releasing peptide and
vasopressin V1A receptors [12]. Indeed, receptors recognized by this
peptide, such as vasopressin and gastrin-releasing peptide receptors,
are expressed by classic and variant SCLC cells, as well as by tumor
cells from other histological origins [30,31]. As a targeting ligand,
antagonist G has the additional advantage of being readily available,
inexpensive to manufacture and easy to handle.
Based on the results presented in the previous section, the cellular
association of antagonist G-targeted CCL or SLP, prepared by the post-
insertion coupling method, was assessed in SCLC cells in order to
evaluate whether such formulations would be selectively targeted to
these cells. The extent of association to SCLC H69 cells for both types of
targeted liposomes was, approximately, 4- to 10-fold higher than thatFig. 3. Quantitative ﬂuorimetric determination of the association of non-targeted and
antagonist G-targeted CCL and SLP to SCLC H69 cells. Tumor cells (0.5×106) were
incubated with: rhodamine-labeled non-targeted, targeted CCL or SLP prepared by
post-insertion (2 mol%), at 0.2 mM of total lipid for 1 h at 37 °C (A), or rhodamine-
labeled non-targeted or targeted SLP at 0.1 or 0.2 mMof total lipid for 1 h at 4 °C or 37 °C
(B). In A, bars are the mean±SD of independent experiments, each one performed in
triplicate. In B, bars are themean±SEM of triplicates of a typical experiment ‘⁎’ symbols
represent the signiﬁcance level (two-way ANOVA, Bonferroni's post-test).
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cellular associationwas dependent both on the lipid concentration and
temperature (Fig. 3B). The signiﬁcant increase observed for the extent
of cellular association upon raising the temperature from 4 °C (a non-
permissive endocytosis condition) to 37 °C is a strong indication that
the particles are actively internalized by tumor cells (Fig. 3B).
The increased cellular association of antagonist G-targeted CCL or
SLP was also veriﬁed in other SCLC cell lines, such as U1285 (data not
shown) and SW2 cells. For all these cells, the homogeneous cellular
association shown by ﬂow cytometry indicated that the liposomes
targeted all tumor cells in a similar extent (shown for SW2 cells,
Fig. 4A). Confocal microscopy analysis of the uptake of the liposomes
labeled with rhodamine-PE (membrane marker, red label) and
encapsulating carboxyﬂuorescein-labeled nucleic acid (green) con-
ﬁrmed that targeted liposomes were internalized by tumor cells in a
higher extent than non-targeted liposomes (Fig. 4B).
Having shown that the targeted liposomes are actively endocytosed,
we were interested in elucidating the main endocytosis pathway
implicated. Different mechanisms of endocytosis can be considered.
Phagocytosis is a very specializedmechanism, usually present in cells of
the immune system [32]. The others are broadly consideredpinocytosis
mechanisms:macropinocytosis, clathrin-mediated endocytosis, caveo-
lin-mediated endocytosis and the less studied endocytosis mechan-
isms, which are independent of both clathrin and caveolin. The
mechanism of internalization of antagonist G-targeted liposomes was
assessed by pre-incubating SCLC H69 cells with drugs described to
selectively inhibit different cell entry pathways before targeted
liposomes were added. Control experiments were ﬁrst performed to
address the cellular association of ﬂuorescein-labeled dextran (a
marker of macropinocytosis), BODIPY-LactoCeramide (a marker of
the caveolae-mediated cell entry pathway), and AlexaF-transferrin, a
“classical” marker of clathrin-mediated endocytosis, as well as the
effect of the selected endocytosis inhibitors on the uptake of these
control markers [33–36]. There was a marked difference in the uptake
of dextran at 4 and 37 °C, indicating the presence of macropinocytosis
mechanisms in SCLC H69 cells, and a moderate inhibitory effect of LY-
294,002 or wortmannin (described as selective macropinocytosis
inhibitors, data not shown). The extent of cellular association of
BODIPY-LactoCeramide was neither statistically different at 37 °C and
4 °C, nor in the presence of inhibitors such as genistein and Filipin
(inhibitors of caveolae-mediated endocytosis, data not shown). These
results suggest that caveolae-mediated endocytosis is not present in
SCLC H69 cells, in accordance with caveolin-1 being not detected in a
large proportion of SCLC cell lines [37,38]. On the other hand, cellular
association of AlexaF-transferrin was partially inhibited upon pre-
incubation of the cells with LY-294,002 and genistein, as well as with
hypertonic medium (0.45 M sucrose, described to selectively inhibitFig. 4. Qualitative evaluation of the association of non-targeted and antagonist G-targeted SL
lipid, for 1 h at 37 °C, followed by assessment of cellular association by ﬂow cytometry (A), or
scan ﬂuorescence microscopy (B). The nucleus was stained with Hoechst (blue), lipid was laclathrin-mediated endocytosis) (Fig. 5A). These results show that there
is lack of LY-294,002 and genistein selectivity formacropinocytosis and
caveolae-mediated endocytosis in H69 cells.
Similarly to the observed with AlexaF-transferrin, both genistein
and, to a less extent, hypertonic medium, inhibited partially the
cellular association of antagonist G-targeted liposomes (40 and 20%
inhibition, respectively, Fig. 5B). However, as shown in the same
Figure, LY-294,002 did not exhibit any signiﬁcant effect on the cellular
association of antagonist G-targeted liposomes, in contrast to its
partial, although signiﬁcant, inhibitory effect on the cellular associ-
ation of AlexaF-transferrin, thus indicating that macropinocytosis and
clathrin-mediated endocytosis do not play an important role in the
uptake of these targeted liposomes.
Taken together, the results from this systematic analysis strongly
suggest that clathrin- and caveolae-independent endocytosis
mechanisms are involved in the internalization of antagonist G-
targeted liposomes into SCLC H69 cells. This is in accordance with the
reports stating that neuroendocrine cells, like SCLC cells, have
clathrin-independent mechanisms of endocytosis, with an important
role in the recovery of membrane proteins after secretion (reviewed
in [32]). However, a small contribution of clathrin-mediated endocy-
tosis, or even of macropinocytosis, for the uptake of antagonist G-
targeted liposomes into SCLC H69 cells cannot be excluded.
Growth factor receptors, such as gastrin releasing peptide and
vasopressin receptors, are not exclusively expressed by SCLC cells
[39,40]. In several types of tumor and endothelial cells of angiogenic
vessels, expression, or even overexpression, of growth factor
receptors is an important mechanism supporting cell proliferation
[41,42]. Therefore, antagonist G-targeted CCL or SLP could be
hypothesized to target cells from different histological origins. Indeed,
antagonist G signiﬁcantly increased the extent of association of CCL or
SLP to cell lines from other types of cancer (relative to non-targeted
liposomes), such as Namalwa (Burkitt's lymphoma), RL (non-
Hodgkin's lymphoma), MCF-7 (breast cancer) and MDA-MB-435S
cells (data not shown). Interestingly, this observation was not
extended to NSCLC A549 cells (Fig. 6A), which shows some selectivity
in the cellular association of targeted formulations. In fact, autocrine
signaling with neuropeptides involving gastrin releasing peptide
receptor, or the expression of V1A receptors, is not present in NSCLC
cells [43,44]. Impressively, however, non-targeted liposomes associ-
ated much more extensively to A549 cells than to SCLC H69 cells
(approximately 7-fold), association that was inhibited upon incuba-
tion of cells at 4 °C (Fig. 5B), andmay be, therefore, attributed to active
cell internalization. This suggests that antagonist G-mediated target-
ing might be important in cells that exhibit low capacity for the
uptake of non-targeted sterically stabilized liposomes. Also of interest,
was the observation of the signiﬁcantly increased association ofPODN to SCLC SW2 cells. Tumor cells were incubated with the liposomes at 0.6 mM total
incubated for an additional 5 h in fresh medium at 37 °C before observation by confocal
beled with rhodamine-PE (red) and ODNwere labeled with carboxyﬂuorescein (green).
Fig. 5. Evaluation of the mechanisms of cellular internalization of antagonist G-targeted liposomes in SCLC H69 cells. The effect of several endocytosis inhibitors on the association of
AlexaF-transferrin (A) and of antagonist G-targeted liposomes (B) to tumor cells was evaluated by ﬂuorimetry. Tumor cells (1×106) were incubated with inhibitors of endocytosis
for 30min, and then incubated with either AlexaF-transferrin at 100 μg/ml or antagonist G-targeted liposomes at 0.1 mM of total lipid, for 1 h, as described in Section 2. The results of
cellular association evaluated by ﬂuorimetry were expressed in percentage relative to those obtained for control cells (without pre-treatment), at 37 °C. Bars are the mean±SD of at
least 3 independent experiments. ‘⁎’ symbol represents the signiﬁcance level of the difference of the mean of inhibitory treatments from 100% (one-sample t test).
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proliferating microvascular endothelial cells (Fig. 6B). Overall, these
results suggest that antagonist G-mediated internalization of lipo-
somes might be valuable in cancer types with different histological
origins and in endothelial cells of angiogenic vessels.
3.4. Assessment of Bcl-2 protein levels in SCLC cells upon transfection
with antagonist G-targeted liposomes containing anti-BCL2 siRNA
We have previously selected an anti-BCL2 siRNA that signiﬁcantly
downregulated Bcl-2 in SCLC SW2 cells in a sequence-speciﬁcmanner,
both at the protein and mRNA levels at a concentration of 50 nM
(unpublished observations). Such sequence was therefore selected to
test the transfection ability of the developed antagonist G-targeted
liposomes (SLP) in SCLC cells. Surprisingly, the improved cellular
association of antagonist G-targeted SLP containing siRNA did not
have any impact on the Bcl-2 protein levels of SCLC SW2 cells relative
to untreated cells (data not shown), as neither did the non-targeted
liposomes nor the antagonist G-targeted liposomes containing a
control non-targeting (nt) sequence. The outcome was the same when
the concentration of siRNA was increased to 4 μM or when double
treatments were attempted (data not shown). These results clearly
indicate that there are a number of biological obstacles, besides
liposomal internalization, that compromise gene silencing. The
absence of Bcl-2 downregulation might be due to an inadequate
release of the nucleic acids from the endocytic pathway, due to the
presence of 10 mol% of PEG incorporated in the SLP formulation [45]
and/or to the absence of membrane destabilizing/fusogenic lipids [3].
PEG plays the double role of preventing aggregation during liposomal
preparation and of modulating biodistribution and pharmacokinetics
of the liposomes [46].Fig. 6. Association of non-targeted and antagonist G-targeted SLPODN with SCLC H69
and NSCLC A549 cells (A), or HMEC-1 endothelial cells (B). Cells were incubated with
rhodamine-labeled SLPODN, either targeted or non-targeted, at 0.2 mM of total lipid, for
1 h at 4 or 37 °C, as indicated. Bars are the mean±SEM, n=3.Tekmira developed SNALP formulations containing siRNA, which
are a good example of a competent-transfecting system targeting the
liver [5,6]. These particles are prepared at an initial−/+ charge ratio
of 1:2 or lower, and incorporate a high proportion of cationic lipid (30
to 40 mol%). The excess of positive charges likely stabilizes the
liposomes in the stepwhere ethanol is present, in such extent that this
procedure demands the incorporation of only 2 mol% of a PEG-
derivatized lipid [4,6], which might, in part, justify their transfection
capabilities. At physiological pH, however, even if the assumed ﬁnal
neutrality of the particles, due to the low pKa of the cationic lipid,
makes them adequate for systemic administration, the reduced
amount of PEG, grafted with a C14 lipid anchor, dramatically limits
their circulation half-life in the blood (72min in cynomolgusmonkeys
and 38 min in mice, [5]). These formulations, while efﬁciently
transfecting the liver, are not so efﬁcient in transfecting subcutaneous
tumors [6]. Targeting distant disease sites (beyond the liver), like
small cell lung cancer, with liposomes, probably does not cope with
such low levels of PEG.
Moreover, the main endocytosis pathways used by antagonist G-
targeted SPL (caveolin- and clathrin-independent endocytosis) might
lead to degradation of the encapsulated nucleic acid. In this respect
not much is known, just that the caveolae-mediated endocytosis
pathway, absent in this type of cell lines [37,38], has been described to
be more efﬁcient in terms of cell transfection than the clathrin-
mediated one [36,47]. The cell entry pathway used by targeted
liposomes incorporating receptor ligands has never been an issue
when delivering small molecular weight drugs, like doxorubicin
[48,49]. However, the scenario seems to be different when this same
system is used to deliver nucleic acids. Only a few examples of
successful targeting of liposomes containing nucleic acids designed
for systemic antitumor therapy have been reported. Even in such
reported cases, the success was limited. GD2-targeted CCL containing
anti-c-myb or anti-c-myc ODNs were active only when used in
multiple treatments every two days (for a minimum of 3 treatments),
at 10 or 20 μM ODN [50,51]. Furthermore, EpCAM-targeted CCL
encapsulating a bispeciﬁc anti- (BCL2 and BCL-xL) gapmer ODN (with
enhanced potency compared to phosphorothioate), required double
treatments of 5 μM ODN, for 4 h each, to achieve 50% to 60% target
silencing (with 25% cytotoxicity) [52]. However, these can be
considered extreme concentrations, difﬁcult to be reached at the
target tumors in vivo.
In the present paper, we were able to generate peptide-targeted
liposomes containing nucleic acids, with high encapsulation efﬁciency
and loading capacity, which signiﬁcantly increased intracellular
accumulation of the encapsulated nucleic acid as compared to non-
targeted liposomes. However, the enhanced cellular association is
merely one of the components towards an efﬁcient transfection of
tumor cells. The past effort to ﬁnd a way to improve cell transfection
has led to the discovery of agents (e.g. fusogenic lipids, peptides or
440 A.O. Santos et al. / Biochimica et Biophysica Acta 1798 (2010) 433–441drugs) that facilitate liposomal-content release from the endocytotic
pathway [24,53,54]. It is interesting to notice that some targeting
ligands themselves, such as transferrin, also actively promote the
endosomal release of the nucleic acids [55]. In the present work, the
absence of Bcl-2 downregulation indicates that additional improve-
ments need to be performed on the liposomal formulation, namely
aiming at ameliorating the access of the nucleic acids to the cytoplasm
of the tumor cells following receptor-mediated endocytosis.
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